{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nogapendekin+Alfa",
    "query": {
      "intervention": "Nogapendekin Alfa"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nogapendekin+Alfa&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T05:46:04.299Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05618925",
      "title": "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin's Lymphoma Refractory/Relapsed"
      ],
      "interventions": [
        {
          "name": "N803",
          "type": "DRUG"
        },
        {
          "name": "CD19t-haNK suspension",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-08-22",
      "completion_date": "2027-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Tyler, Texas",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05618925"
    },
    {
      "nct_id": "NCT06061809",
      "title": "N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "Tumor Treating Fields (TTFields, 200 kHz)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2024-08-07",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 4,
      "location_summary": "El Segundo, California • Fullerton, California • Newport Beach, California + 1 more",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06061809"
    },
    {
      "nct_id": "NCT07261657",
      "title": "N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Myxoid Liposarcoma",
        "Round Cell Liposarcoma",
        "Synovial Sarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nogapendekin Alfa Inbakicept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Seth Pollack",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 8,
      "start_date": "2026-04-13",
      "completion_date": "2032-09-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07261657"
    },
    {
      "nct_id": "NCT03520686",
      "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NAI + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Nivolumab + Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2018-05-18",
      "completion_date": "2025-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 31,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520686"
    },
    {
      "nct_id": "NCT07355205",
      "title": "First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer Stage IV",
        "Non-small Cell Lung Cancer Recurrent"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nogapendekin alfa inbakicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2026-07-07",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07355205"
    },
    {
      "nct_id": "NCT05096663",
      "title": "Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Advanced Lung Non-Small Cell Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cobalamin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nogapendekin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 82,
      "start_date": "2022-03-15",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 350,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096663"
    },
    {
      "nct_id": "NCT06956547",
      "title": "Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Lymphopenia"
      ],
      "interventions": [
        {
          "name": "nogapendekin-alfa inbakicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06956547"
    },
    {
      "nct_id": "NCT07123727",
      "title": "A Study to Examine Anktiva for the Treatment of COVID-19.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Long COVID Syndrome",
        "Long Covid 19"
      ],
      "interventions": [
        {
          "name": "Anktiva",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-04",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07123727"
    },
    {
      "nct_id": "NCT07108036",
      "title": "A Study to Assess Anktiva in Patients With Long Covid-19.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID"
      ],
      "interventions": [
        {
          "name": "N-803 (IL-15 Superagonist)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-11-14",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07108036"
    },
    {
      "nct_id": "NCT05419011",
      "title": "Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Carcinoma",
        "Colorectal Neoplasm",
        "Lynch Syndrome"
      ],
      "interventions": [
        {
          "name": "Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Colonoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nogapendekin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2023-05-08",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-09-25T05:46:04.299Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05419011"
    }
  ]
}